Cargando…

Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition

BACKGROUND: Epithelial to mesenchymal transition (EMT), implicated as a mechanism for tumor dissemination, is marked by loss of E-cadherin, disruption of cell adhesion, and induction of cell motility and invasion. In most intraductal breast carcinomas E-cadherin is regulated epigenetically via methy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Yvonne L, Shepard, Christopher R, Wells, Alan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907333/
https://www.ncbi.nlm.nih.gov/pubmed/20609236
http://dx.doi.org/10.1186/1476-4598-9-179
_version_ 1782184101050056704
author Chao, Yvonne L
Shepard, Christopher R
Wells, Alan
author_facet Chao, Yvonne L
Shepard, Christopher R
Wells, Alan
author_sort Chao, Yvonne L
collection PubMed
description BACKGROUND: Epithelial to mesenchymal transition (EMT), implicated as a mechanism for tumor dissemination, is marked by loss of E-cadherin, disruption of cell adhesion, and induction of cell motility and invasion. In most intraductal breast carcinomas E-cadherin is regulated epigenetically via methylation of the promoter. E-cadherin expression is therefore dynamic and open to modulation by the microenvironment. In addition, it has been observed that metastatic foci commonly appear more differentiated than the primary tumor, suggesting that cancer cells may further undergo a mesenchymal to epithelial reverting transition (MErT) in the secondary organ environment following the EMT that allows for escape. RESULTS: We first examined E-cadherin expression in primary breast tumors and their corresponding metastases to liver, lung and brain and discovered that 62% (10/16) of cases showed increased E-cadherin expression in the metastases compared to the primaries. These observations led to the question of whether the positive metastatic foci arose from expansion of E-cadherin-positive cells or from MErT of originally E-cadherin-negative disseminated cells. Thus, we aimed to determine whether it was possible for the mesenchymal-like MDA-MB-231 breast cancer cells to undergo an MErT through the re-expression of E-cadherin, either through exogenous introduction or induction by the microenvironment. Ectopic expression of full-length E-cadherin in MDA-MB-231 cells resulted in a morphological and functional reversion of the epithelial phenotype, with even just the cytosolic domain of E-cadherin yielding a partial phenotype. Introduction of MDA-MB-231 cells or primary explants into a secondary organ environment simulated by a hepatocyte coculture system induced E-cadherin re-expression through passive loss of methylation of the promoter. Furthermore, detection of E-cadherin-positive metastatic foci following the spontaneous metastasis of MDA-MB-231 cells injected into the mammary fat pad of mice suggests that this re-expression is functional. CONCLUSIONS: Our clinical observations and experimental data indicate that the secondary organ microenvironment can induce the re-expression of E-cadherin and consequently MErT. This phenotypic change is reflected in altered cell behavior and thus may be a critical step in cell survival at metastatic sites.
format Text
id pubmed-2907333
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29073332010-07-21 Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition Chao, Yvonne L Shepard, Christopher R Wells, Alan Mol Cancer Research BACKGROUND: Epithelial to mesenchymal transition (EMT), implicated as a mechanism for tumor dissemination, is marked by loss of E-cadherin, disruption of cell adhesion, and induction of cell motility and invasion. In most intraductal breast carcinomas E-cadherin is regulated epigenetically via methylation of the promoter. E-cadherin expression is therefore dynamic and open to modulation by the microenvironment. In addition, it has been observed that metastatic foci commonly appear more differentiated than the primary tumor, suggesting that cancer cells may further undergo a mesenchymal to epithelial reverting transition (MErT) in the secondary organ environment following the EMT that allows for escape. RESULTS: We first examined E-cadherin expression in primary breast tumors and their corresponding metastases to liver, lung and brain and discovered that 62% (10/16) of cases showed increased E-cadherin expression in the metastases compared to the primaries. These observations led to the question of whether the positive metastatic foci arose from expansion of E-cadherin-positive cells or from MErT of originally E-cadherin-negative disseminated cells. Thus, we aimed to determine whether it was possible for the mesenchymal-like MDA-MB-231 breast cancer cells to undergo an MErT through the re-expression of E-cadherin, either through exogenous introduction or induction by the microenvironment. Ectopic expression of full-length E-cadherin in MDA-MB-231 cells resulted in a morphological and functional reversion of the epithelial phenotype, with even just the cytosolic domain of E-cadherin yielding a partial phenotype. Introduction of MDA-MB-231 cells or primary explants into a secondary organ environment simulated by a hepatocyte coculture system induced E-cadherin re-expression through passive loss of methylation of the promoter. Furthermore, detection of E-cadherin-positive metastatic foci following the spontaneous metastasis of MDA-MB-231 cells injected into the mammary fat pad of mice suggests that this re-expression is functional. CONCLUSIONS: Our clinical observations and experimental data indicate that the secondary organ microenvironment can induce the re-expression of E-cadherin and consequently MErT. This phenotypic change is reflected in altered cell behavior and thus may be a critical step in cell survival at metastatic sites. BioMed Central 2010-07-07 /pmc/articles/PMC2907333/ /pubmed/20609236 http://dx.doi.org/10.1186/1476-4598-9-179 Text en Copyright ©2010 Chao et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Chao, Yvonne L
Shepard, Christopher R
Wells, Alan
Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
title Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
title_full Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
title_fullStr Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
title_full_unstemmed Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
title_short Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
title_sort breast carcinoma cells re-express e-cadherin during mesenchymal to epithelial reverting transition
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907333/
https://www.ncbi.nlm.nih.gov/pubmed/20609236
http://dx.doi.org/10.1186/1476-4598-9-179
work_keys_str_mv AT chaoyvonnel breastcarcinomacellsreexpressecadherinduringmesenchymaltoepithelialrevertingtransition
AT shepardchristopherr breastcarcinomacellsreexpressecadherinduringmesenchymaltoepithelialrevertingtransition
AT wellsalan breastcarcinomacellsreexpressecadherinduringmesenchymaltoepithelialrevertingtransition